S&P 500 Healthcare Sector SEC Filings — April 07, 2026

07-04-2026

Energy Transition Special Opportunities (formerly Climate Transition Special Opportunities SPAC I) filed an amended S-1/A registration statement on April 7, 2026, for an IPO of Firm Units targeting $150,000,000 in gross proceeds (implied 15 million units at $10 each), with an over-allotment option for up to 2,250,000 additional units. Proceeds from Firm Units and Private Placement will be deposited into a trust account, including a 4.0% deferred underwriting commission of $6,000,000 (up to $900,000 for Option Units). The Sponsor holds 5,750,000 Founder Shares issued for a total of $25,000, with warrants exercisable at $11.50 per share post-Business Combination.

• ·Warrants entitle holder to purchase one Ordinary Share for $11.50, exercisable 30 days after Business Combination, expiring five years after or upon redemption/liquidation
• ·Over-allotment Option exercisable within 45 days of Registration Statement effective date
• ·Company name changed from Climate Transition Special Opportunities SPAC I on September 15, 2025
• ·Founder Shares issued July 30, 2025, with 1-for-1.26605495295 share split on September 4, 2025; 75,000 transferred to director nominees

07-04-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on April 7, 2026, disclosing a press release announcing that its RAD division is implementing its first hardware price increase in nearly three years due to market conditions demanding adjustment. The press release is attached as Exhibit 99.1 and furnished under Item 8.01, not deemed filed or material.

• ·Filing explicitly states information is furnished, not filed, and not deemed material.
• ·Date of earliest event reported: April 7, 2026.

07-04-2026

Flushing Financial Corporation's stockholders overwhelmingly approved the merger proposal with OceanFirst Financial Corp. at a special meeting on April 2, 2026, with 24,102,136 votes in favor (97.3% of shares represented), 628,640 against, and 40,182 abstentions out of 24,770,958 shares represented (73.1% quorum of 33,883,626 outstanding shares). However, the advisory compensation proposal for named executive officers passed narrowly with 12,435,187 votes for (50.2%) versus 12,222,100 against and 113,671 abstentions. Under the merger terms, each Flushing share will convert to 0.85 shares of OceanFirst common stock.

• ·Joint press release issued April 6, 2026, announcing voting results.
• ·Merger involves two-step process: Merger Sub into Flushing, then Flushing into OceanFirst.
• ·OceanFirst stockholder meeting also held April 2, 2026.
• ·Proposed Warburg Pincus investment in OceanFirst equity securities.

07-04-2026

Protagenic Therapeutics, Inc. notified Alexander Arrow, MD, its Chief Financial Officer, that his employment will be terminated effective April 30, 2026, with the board notification occurring on March 31, 2026. No replacement has been announced, representing a key leadership transition. The filing was signed by Executive Chairman Garo H. Armen.

• ·Filing signed on April 6, 2026, and dated April 7, 2026

07-04-2026

News Corporation disclosed copies of information provided to the Australian Securities Exchange (ASX) regarding its ongoing stock repurchase program, under which the company is authorized to acquire up to $1 billion in aggregate of its outstanding Class A common stock (NWSA) and Class B common stock (NWS). These disclosures (Exhibits 99.1-99.4) detail daily ASX notifications as required under ASX rules and include forward-looking statements about potential repurchases subject to market conditions and other factors.

• ·Date of earliest event reported: April 2, 2026
• ·Filing signed and dated: April 7, 2026

07-04-2026

At the April 2, 2026 special stockholder meeting, OceanFirst Financial Corp. shareholders approved the issuance proposal for common stock to Flushing Financial Corporation merger holders and Warburg Pincus affiliates (42,020,260 for, 2,526,694 against, 176,895 abstentions), representing a strong endorsement of the merger and investment. However, the charter amendment to exempt Warburg from certain ownership restrictions was rejected (18,408,853 for, 26,148,179 against, 166,817 abstentions), potentially complicating the transaction. A quorum was met with 44,723,849 shares present out of 57,402,016 outstanding.

• ·Record date for special meeting: February 20, 2026
• ·Joint proxy statement/prospectus dated February 26, 2026
• ·Joint press release issued April 6, 2026 announcing voting results

07-04-2026

Baring Financial LLC filed its 13F-HR on April 7, 2026, reporting holdings as of March 31, 2026, with a total portfolio value of $163480928 across 72 positions held solely on a discretionary basis. The portfolio emphasizes ETFs such as iShares Core S&P 500 ETF valued at $15796176 and Schwab Strategic TR US LCAP VA ETF at $7180193, alongside individual stocks including Berkshire Hathaway Inc. DEL CL B NEW at $4873943, Apple Inc. at $2835160, and NVIDIA Corporation at $2865400. No changes in holdings were indicated in the filing.

• ·Filing CIK: 0002052588
• ·Filer address: 1310 10th Street Suite 101, Bellingham, WA 98225
• ·All positions reported with sole discretionary voting authority and no indicated additions, reductions, or other changes

07-04-2026

Rosenberg Matthew Hamilton filed a 13F-HR on April 7, 2026, disclosing sole discretionary holdings as of March 31, 2026, in a diversified portfolio emphasizing ETFs and individual stocks. Top positions include Vanguard Total Stock Market ETF (45382127 USD market value, 141461 shares), Vanguard Intermediate-Term Corporate Bond ETF (39262227 USD, 474468 shares), and JPMorgan Ultra-Short Income ETF (36313681 USD, 717520 shares), with additional exposure to stocks like Microsoft (7442 shares), Ford Motor (15636 shares), and Starbucks (3355 shares). The portfolio features no reported changes, puts, or calls across 200+ positions spanning U.S. equities, bonds, international, and commodities.

• ·Filing CIK: 0001812103
• ·SEC File Number: 028-20259
• ·Address: 200 Grand Avenue, Ste. 205, Grand Junction, CO 81501
• ·Phone: 9707735300
• ·Over 200 positions reported, all sole discretionary with no puts/calls

07-04-2026

CVB Financial Corp.'s definitive proxy statement (DEF 14A) dated April 7, 2026, outlines the 2026 annual shareholder meeting on May 20, 2026, at 8:00 a.m. PDT in Ontario, CA, with proposals to elect 10 directors (or 8 if the proposed merger with Heritage Commerce Corp is not completed), approve on an advisory basis the 2025 named executive officer compensation, and ratify KPMG LLP as independent auditors for 2026. Continuing director nominees include George A. Borba, Jr., Jane Olvera Majors, David A. Brager, Raymond V. O’Brien III, Stephen A. Del Guercio, Hal W. Oswalt, Anna Kan, and Timothy Stephens; contingent nominees are Julianne Biagini-Komas and R. Clay Jones. The record date for voting eligibility is March 26, 2026.

• ·Meeting location: CVB Financial Corp. Corporate Headquarters, 701 North Haven Avenue, Ontario, CA 91764.
• ·Audio conference call access: Dial 1 (833) 630-1956; replay access code 1160694 until May 27, 2026.
• ·Proxy materials available at https://investors.cbbank.com/annual-meeting.

07-04-2026

Bread Financial Holdings, Inc. issued a DEFA14A filing providing notice of the availability of proxy materials for its Annual Meeting of Stockholders on May 19, 2026, for stockholders of record as of March 25, 2026. The meeting agenda includes the election of nine director nominees, an advisory vote to approve executive compensation, approval of the 2026 Employee Stock Purchase Plan, and ratification of Deloitte & Touche LLP as the independent registered public accounting firm for 2026. The Board of Directors recommends voting FOR all nominees and FOR Proposals 2, 3, and 4.

• ·Paper materials can be ordered via www.investorelections.com/BFH, call 1-866-648-8133, or email paper@investorelections.com using the 12-digit control number.
• ·Meeting covers year ended December 31, 2025.
• ·Proposal 5 covers any other business as may properly come before the meeting or adjournments.

07-04-2026

Artelo Biosciences filed an S-1 registration statement on April 7, 2026, to register up to 9,820,294 shares for resale by selling stockholders from its March 2026 private placement, which raised gross proceeds of $10,996,902.70 (net $10,031,902.37) through issuance of 81,000 common shares, pre-funded warrants for 3,107,407 shares, and common warrants for 6,376,814 shares. Recent developments include regaining Nasdaq compliance on April 6, 2026, after a 1-for-3 reverse stock split effective March 10, 2026, reducing outstanding shares from 2,124,772 to 736,127, and full repayment of bridge notes totaling $665,300 principal by early April; however, substantial future share issuances pose dilution risks.

• ·Reverse stock split effective March 10, 2026, reduced authorized common shares from 500,000,000 to 166,666,667 and preferred shares from 69,444 to 23,148.
• ·Nasdaq compliance with Listing Rule 5550(b)(1) ($2,500,000 minimum stockholders’ equity) required by March 30, 2026, and confirmed April 6, 2026; subject to Mandatory Panel Monitor through April 6, 2027.
• ·Common Warrants exercisable for 5.5 years from Initial Registration Statement effective date at $3.20 per share; Placement Agent Warrants at $4.3125 per share.
• ·Company qualifies as smaller reporting company with reduced disclosure obligations.

07-04-2026

Civista Bancshares, Inc. filed its DEF 14A Proxy Statement on April 7, 2026, detailing board committee compositions and activities for 2025, including the Compensation Committee (5 members, 3 meetings) and Board Risk Committee (7 members, 4 meetings). Non-employee directors received $1,750 per Bank board meeting, $600 per committee meeting ($1,600 for chairs), and a $20,000 annual retainer paid entirely in common shares for Bank board service from April 15, 2025, to May 19, 2026. No directors elected to defer fees under the non-qualified Deferred Compensation Plan in 2025.

• ·Board Risk Committee established in July 2023 to oversee risk appetite and ERM Policy covering credit, market, liquidity, compliance, operational, legal, reputational, and strategic risks.
• ·Audit Committee oversees independent auditors and material related party transactions.
• ·Compensation Committee approves executive officer compensation and benefit programs.

07-04-2026

Sprout Social, Inc. (SPT) filed a DEFA14A form on April 07, 2026, consisting of Definitive Additional Materials for its Schedule 14A Proxy Statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing is soliciting material under §240.14a-12, with no fee required. No financial metrics, proposals, or substantive details are provided in the document header.

07-04-2026

Financially Speaking Inc filed its 13F-HR on April 7, 2026, disclosing sole discretionary holdings as of March 31, 2026, in over 100 equity and ETF positions. Top holdings by market value include J P MORGAN EXCHANGE TRADED F ULTRA SHRT ETF (7534514 or $7,534,514,000) and FIDELITY MERRIMACK STR TR LOW DURTIN ETF (7529973 or $7,529,973,000), followed by PALANTIR TECHNOLOGIES INC CL A (757146 or $757,146,000) and NVIDIA CORPORATION COM (438616 or $438,616,000). The portfolio shows heavy concentration in short-duration fixed income ETFs with diversified exposure to technology, energy, and consumer staples stocks; no prior period data is provided for comparisons.

• ·Filing CIK: 0002040901
• ·Filer address: 5889 GREENWOOD PLAZA BLVD. SUITE 400, GREENWOOD VILLAGE, CO 80111
• ·All reported holdings are sole discretionary (SOLE); no shared or other voting authority indicated
• ·SEC file number: 028-24901

07-04-2026

The proxy statement solicits votes for the annual stockholder meetings of abrdn Asia-Pacific Income Fund, Inc. (FAX) and abrdn Australia Equity Fund, Inc. (IAF) on May 27, 2026, at 9:30 a.m. ET, to elect one Class II Director for each fund for a three-year term and, for IAF only, to consider the continuation of one Director's term under Corporate Governance Policies. P. Gerald Malone is retiring as Class II Director, prompting the nomination of Christian Pittard (current Class I Director of FAX) as Class II Director for FAX to balance director classes. Record Date is April 1, 2026, with no financial performance metrics or changes reported.

• ·Meetings held at offices of abrdn Inc., 1900 Market Street, Suite 200, Philadelphia, PA 19103.
• ·Proxy materials available at http://www.aberdeenfax.com (FAX) and http://www.aberdeeniaf.com (IAF).
• ·Fiscal year ended October 31, 2025; annual reports available upon request via 1-800-522-5465.
• ·Voting requires majority or plurality as specified; quorum is majority of shares present.
• ·No dissenters' rights of appraisal.

07-04-2026

Viewbix Inc. filed an S-3 shelf registration statement on April 7, 2026, to register securities for potential future sales by selling stockholders. Key recent developments include the March 4, 2026 closing of the Quantum acquisition, issuing up to 40.0% of outstanding stock (2,666,000 shares and pre-funded warrants for 4,447,595 shares) for 100% of Quantum, with potential earn-out securities up to 12,702,847 shares; and a January 2026 amended private placement of 800,000 shares (or pre-funded warrants) at $1.75 each with warrants for 640,000 shares. The company previously reduced its digital advertising operations and sales/R&D team due to failure to meet sales targets set in the 2020 recapitalization.

• ·Quantum Closing Date: March 4, 2026; 12-month lock-up on Viewbix Exchange Shares and exercise warrants.
• ·Earn-Out Securities issuable only after 12-month anniversary of Quantum Closing Date upon milestones: up to 1,975,998 shares for 5 patent applications; 3,436,519 for $20M+ Portfolio Company event; 7,290,330 for $250M+ valuation event.
• ·Pre-Funded Warrants exercisable at $0.0001 (Quantum Exchange) or $0.00001 (Private Placement) per share, no expiration until exercised.
• ·Common Warrants expire 5 years from issuance.
• ·Reverse Split: one-for-four on March 14, 2025; all share references post-split.

07-04-2026

Jefferies Financial Group Inc. reported total revenues of $2,871,265 thousand for the three months ended February 28, 2026, up 16.1% YoY from $2,472,864 thousand, with investment banking revenues surging 39.5% to $1,018,284 thousand and commissions up 27.5% to $367,604 thousand, though asset management fees declined 21.1% to $67,362 thousand. Net revenues increased 26.6% YoY to $2,017,130 thousand, but non-interest expenses rose 25.2% to $1,804,914 thousand, primarily due to 29.2% higher compensation and benefits at $1,085,890 thousand, resulting in net earnings of $159,346 thousand, up 16.4% YoY. Total assets stood at $74,380,490 thousand as of February 28, 2026, down 2.1% QoQ from $76,012,347 thousand.

• ·Diluted EPS of $0.70, up from $0.57 YoY.
• ·Net cash used in operating activities: $1,737,291 thousand (worsened from $2,665,165 thousand YoY).
• ·Common stock repurchases: $174,303 thousand in financing activities.

07-04-2026

Amgen Inc. filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting of Stockholders, to be held virtually on May 19, 2026, at 11:00 A.M. Pacific Time, for holders as of March 20, 2026. Key proposals include electing 12 director nominees (all board-recommended FOR), an advisory vote to approve executive compensation (FOR), ratification of Ernst & Young LLP as auditors for fiscal year ending December 31, 2026 (FOR), and a stockholder proposal requiring an independent board chairman (board recommends AGAINST). Voting must be completed by May 18, 2026 11:59 PM ET for direct shares or May 14, 2026 for Amgen-sponsored plans.

• ·Record date for meeting eligibility: March 20, 2026
• ·Proxy materials request deadline: May 5, 2026
• ·Virtual meeting URL: www.virtualshareholdermeeting.com/AMGN2026
• ·Control numbers referenced for voting: V91788-P49460, V91789-P49460

07-04-2026

Editas Medicine, Inc. dismissed Ernst & Young LLP as its independent registered public accounting firm on April 1, 2026, effective immediately, and appointed PricewaterhouseCoopers LLP as the new firm for the fiscal year ending December 31, 2026, following a thorough review by the Audit Committee. There were no disagreements or reportable events with Ernst & Young during the fiscal years ended December 31, 2024 and 2025, or the interim period through April 1, 2026, and Ernst & Young's audit reports were unqualified. The Company had no prior consultations with PwC on accounting matters.

• ·Audit Committee solicited proposals from other firms before decision.
• ·Company notified Ernst & Young on April 2, 2026.
• ·Ernst & Young letter dated April 7, 2026, filed as Exhibit 16.1, confirming agreement with disclosures.
• ·No prior consultations with PwC during fiscal years 2024, 2025, or interim through April 1, 2026.

07-04-2026

Cintas Corp reported robust Q3 FY2026 results with total revenue of $2,841,444 thousand, up 8.9% YoY from $2,609,159 thousand, driven by uniform rental and facility services (+7.8%) and other revenue (+12.9%), while net income rose 8.5% YoY to $502,496 thousand. For the nine months ended February 28, 2026, revenue increased 8.9% YoY to $8,359,558 thousand and net income grew 9.2% to $1,488,979 thousand, with diluted EPS at $3.65 versus $3.31 prior year. However, cash and equivalents declined to $183,204 thousand from $243,428 thousand YoY and $263,973 thousand at fiscal year-start, reflecting $933,227 thousand in share repurchases, $520,850 thousand in dividends, and $299,107 thousand in capital expenditures.

• ·Capital expenditures nine months: $299,107 thousand vs $294,260 thousand prior year (+1.6%).
• ·Acquisitions of businesses nine months: $102,685 thousand vs $198,808 thousand prior year (decline).
• ·Diluted EPS three months: $1.24 vs $1.13 YoY (+9.7%).
• ·Dividends declared per share nine months: $1.35 vs $1.17 YoY (+15.4%).
• ·Total shareholders' equity: $4,788,383 thousand vs $4,684,481 thousand at May 31, 2025 (+2.2%).
• ·Short-term debt: $229,490 thousand (new issuance of commercial paper).

07-04-2026

New Fortress Energy Inc., through its subsidiary NFE Power PR LLC, completed the sale of certain turbines (Equipment) to Macquarie Energy LLC for $265,882,500 on April 1, 2026, as part of a sale-leaseback transaction. NFE Turbines LLC, another subsidiary, entered into a 10-year Master Lease Agreement to lease the Equipment back from Macquarie, expected to commence on July 1, 2026, with the parent company providing guarantees for both agreements. The net proceeds were used to repay certain indebtedness, providing immediate liquidity while introducing a long-term lease obligation.

• ·Transaction reported under Items 1.01 (Entry into Material Definitive Agreement) and 2.03 (Creation of Direct Financial Obligation)
• ·Lease term: 10 years
• ·Lease expected to begin: July 1, 2026
• ·Company provides parent guarantee for Lessee’s obligations under the Lease and Seller’s obligations under the Purchase Agreement

07-04-2026

NovaBridge Biosciences reported no revenues for the third consecutive year in 2025, with R&D expenses surging 189% YoY to $62.9M and total operating loss widening to $94.3M from $51.4M in 2024. However, net cash used in operating activities from continuing operations improved to $20.6M (from $52.7M), bolstered by a $61.7M net underwritten offering, resulting in cash and equivalents rising 209% to $210.6M. Net loss attributable to NovaBridge increased to $46.3M from $22.2M YoY, though per share loss improved slightly to $(0.21) amid share dilution.

• ·Audited by PricewaterhouseCoopers LLP (PCAOB ID 238) and PricewaterhouseCoopers Zhong Tian LLP (PCAOB ID 1424).
• ·ADS issuance/cancellation/distribution fees up to $5.00 per 100 ADSs.
• ·Weighted-average ordinary shares basic/diluted: 220,258,932 in 2025 vs 186,728,372 in 2024.
• ·Net loss per ADS basic/diluted: $(0.48) in 2025 (improved from $(0.27) in 2024).

07-04-2026

SmartFinancial, Inc. (SMBK) filed a DEFA14A Definitive Additional Proxy Materials on April 07, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is marked as Definitive Additional Materials. No specific proposals, financial data, or other substantive details are provided in the filing header.

• ·Filing Type: DEFA14A (Schedule 14A Information)
• ·Filed by the Registrant
• ·No fee required

07-04-2026

First Citizens Financial Corp filed its 13F-HR on April 7, 2026, disclosing $211.8 billion in total 13F holdings value across 136 positions as of March 31, 2026. The diversified portfolio includes large share positions in ETFs such as iShares Dow Jones Technology (9,001,700 shares sole) and iShares Dow Jones Healthcare (9,288,000 shares sole), as well as individual stocks like Apple Inc (2,172,400 shares sole) and Bank of America Corp (1,387,600 shares sole). This quarterly snapshot provides no period-over-period comparisons.

• ·CIK: 0001800597
• ·Business address: 2601 4TH ST SW, Mason City, IA 50401
• ·Phone: 641-422-1600
• ·All holdings reported as sole discretionary voting authority

07-04-2026

USANA Health Sciences, Inc. filed its DEF 14A proxy statement on April 7, 2026, for the virtual Annual Meeting of Shareholders on May 20, 2026, at 11:00 AM MDT, with a record date of March 16, 2026. Shareholders are asked to vote on electing eight directors, ratifying KPMG LLP as the independent registered public accounting firm for Fiscal Year 2026, and approving executive compensation on an advisory basis. The proxy materials are provided via 'notice and access' model to reduce costs and conserve resources.

• ·Annual Meeting accessible via www.virtualshareholdermeeting.com/USNA2026 using 16-digit control number.
• ·No in-person attendance option; voting available online, by phone, or mail.
• ·Proxy materials include 2025 Annual Report on Form 10-K.

07-04-2026

Tianci International, Inc. (CIIT) received a Nasdaq deficiency notice on October 29, 2025, for its common stock closing bid price being below the $1.00 minimum for 30 consecutive business days under Listing Rule 5550(a)(2), with a compliance deadline of April 27, 2026. On April 6, 2026, Nasdaq informed the company that it has regained compliance with the Bid Price Requirement. The matter is now closed with no further action required.

• ·Securities: Common Stock, par value $0.0001, Trading Symbol CIIT
• ·Nasdaq Listing Rule: 5550(a)(2) (Bid Price Requirement)
• ·Compliance grace period: 180 calendar days
• ·Company address: Unit 1109, Lippo Sun Plaza, 28 Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong 999077
• ·Former names: Steampunk Wizards, Inc. (changed 20150702), FREEDOM PETROLEUM INC. (changed 20120910)

07-04-2026

Capital One Financial Corporation completed its acquisition of Brex Inc. on April 7, 2026, for approximately $2.56 billion in cash and 10,646,306 shares of common stock, pursuant to a Merger Agreement dated January 22, 2026. The cash payment is subject to customary post-closing adjustments, and the stock issuance was exempt from registration under Section 4(a)(2) of the Securities Act. The Board also approved a special award of 11,041 restricted stock units valued at approximately $2.0 million to Frank LaPrade, Chief Enterprise Services Officer and Chief of Staff to the CEO, for his contributions to the transaction and anticipated integration work.

• ·Merger Agreement dated January 22, 2026.
• ·RSUs vest in three equal annual installments on the first, second, and third anniversaries of the grant date, settling 100% in Company Common Stock.
• ·Cash payment subject to customary post-closing adjustment.

07-04-2026

Calder Financial LLC filed its quarterly 13F-HR report disclosing 40 equity holdings with a total market value of $100,733,930 as of March 31, 2026. The portfolio is dominated by Vanguard ETFs and index funds, including the largest position of 330,287 shares in Vanguard Ultra-Short Bond ETF and 190,042 shares in Vanguard Short-Term Treasury ETF. Notable individual stock holdings include Microsoft Corp (3,976 shares), Nvidia Corp (3,796 shares), and Apple Inc (1,791 shares), with all positions held under sole voting power.

• ·Filing date: April 07, 2026
• ·Report period end: March 31, 2026
• ·All holdings reported with sole voting power (no shared or other power)
• ·Firm address: 24 Founders Way, Downingtown, PA 19335

07-04-2026

Ellington Financial Inc. announced on April 7, 2026, that its Board of Directors declared a monthly dividend of $0.13 per share on common stock, payable on May 29, 2026, to stockholders of record as of April 30, 2026. The press release is filed as Exhibit 99.1.

• ·Securities registered on NYSE: Common Stock (EFC), Series B Preferred (EFC PR B), Series C Preferred (EFC PR C), Series D Preferred (EFC PRD)
• ·Company address: 53 Forest Avenue, Old Greenwich, CT 06870

07-04-2026

SCI Engineered Materials, Inc. filed a DEF 14A proxy statement for its Annual Meeting of Shareholders on May 19, 2026, seeking to elect six directors (Vince Crisler, John P. Gilliam, Emily Lu, Laura F. Shunk, Charles Wickersham, and Jeremiah R. Young) and ratify the independent registered public accounting firm for the year ending December 31, 2026. The record date is March 30, 2026, with 4,450,003 shares of common stock outstanding; officers, directors, and nominees beneficially own 19.3% of the shares and intend to vote in favor of the proposals. No other financial metrics or period-over-period comparisons are disclosed in the filing.

• ·Annual Meeting location: 2839 Charter Street, Columbus, Ohio 43228 at 9:30 a.m. EDT on May 19, 2026
• ·Voting requires plurality for director election and auditor ratification; quorum is majority of outstanding shares
• ·Proxy materials and 2025 Form 10-K available at www.sciengineeredmaterials-proxy.com or www.InvestorVote.com
• ·XBRL tags reference compensation disclosures for Jeremiah R. Young (PEO) and Gerald S. Blaskie (Non-PEO NEO) for 2023-2025, but no specific amounts provided in text

07-04-2026

Jackson Financial Inc. (JXN-PA) has filed DEFA14A additional proxy materials for its 2026 Annual Meeting on May 21, 2026, at 9:30 A.M. EDT in Lansing, Michigan. Key proposals include the election of nine director nominees, ratification of KPMG LLP as independent auditor for 2026, and a non-binding advisory vote to approve executive compensation, with the Board recommending a FOR vote on all items. This is a standard procedural notice with no financial performance data or changes reported.

• ·Vote deadline: May 20, 2026, 11:59 PM EDT
• ·Material request deadline: May 7, 2026
• ·Meeting location: 1 Corporate Way, Lansing, MI 48951
• ·Online voting: www.ProxyVote.com
• ·Proxy materials available online or by request via 1-800-579-1639 or sendmaterial@proxyvote.com

07-04-2026

On April 7, 2026, Zeo ScientifiX, Inc. (ZEOX) filed an 8-K announcing its selection as a Qualified Team advancing to the Semi-Finals stage of the XPRIZE Healthspan competition via a press release (Exhibit 99.1). This milestone highlights the company's progress in the competition. No financial impacts or metrics were disclosed.

• ·Filing includes Exhibit 99.1: Press Release dated April 7, 2026
• ·Company address: 3321 College Avenue, Suite 246, Davie, Florida 33314
• ·Registrant details: Nevada incorporation, Commission File Number 000-55008, IRS EIN 47-4180540

07-04-2026

Thermo Fisher Scientific Inc. (TMO) filed a Definitive Additional Proxy Statement (DEFA14A) on April 07, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee is required and is marked as Definitive Additional Materials. No substantive proxy details, financial metrics, or changes are disclosed in the provided document header.

07-04-2026

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) announced the appointment of Richard Marshall, M.D., as Chief Medical Officer on a full-time basis, effective June 29, 2026, transitioning from his current role as Medical Director since January 2025. Dr. Marshall, an experienced interventional radiologist, will lead medical strategy, clinical development, and strategic initiatives for the company's PEDD platform and oncology products. The move is positioned to accelerate clinical and economic data advancement amid strong physician engagement, with no reported setbacks in leadership transition.

• ·Dr. Marshall's background includes interventional radiology fellowship at Weill Cornell and Memorial Sloan Kettering, faculty roles at LSU Health Sciences Center and Tulane University.
• ·Company's FDA-cleared devices utilize PEDD for hepatic arterial infusion (liver tumors) and pancreatic retrograde venous infusion (pancreatic tumors).
• ·TriSalus is in final stages of data completion for phase 1 clinical trials of nelitolimod and plans to explore partnerships.

07-04-2026

Pulse Biosciences, Inc. announced the first patient enrollments in its NANOPULSE-AF pivotal clinical study evaluating the nPulse™ Cardiac Catheter System for treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation. The first seven patients were treated at St. Bernards Medical Center in Jonesboro, Arkansas, by Principal Investigator Devi Nair, MD. The multicenter study plans to enroll approximately 215 participants across multiple sites, with primary endpoints assessed at 6 and 12 months post-ablation for procedural success and safety.

• ·Study conducted at St. Bernards Medical Center in Jonesboro, Arkansas
• ·Primary endpoints measure procedural success and safety outcomes

07-04-2026

Bankwell Financial Group, Inc. filed a DEFA14A Definitive Additional Materials proxy statement on April 07, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing, marked as non-preliminary and non-confidential, was submitted by the registrant with no fee required. No specific proposals, financial data, or shareholder actions are detailed in the provided filing header.

07-04-2026

MVB Financial Corp. (MVBF) filed a DEFA14A Definitive Additional Proxy Materials on April 07, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing was made by the registrant with no fee required. No substantive proxy details, financial data, or voting matters are included in the provided content.